Abstract: Taxol is one of the most effective anti-cancer drugs ever developed. The natural source of taxol is the inner bark of several Taxus species, but it accumulates at a very low concentration and with a prohibitively high cost of extraction. Another problem is that the use of inner bark for taxol production implies the destruction of yew trees. For all these reasons, the growing demand for taxol greatly exceeds the supply that can be sustained by isolation from its natural source and alternative sources of the drug are being sought. Although taxol has been prepared by total synthesis, the process is not commercially viable. Taxol can also be semisynthetically produced via the conversion of baccatin III or 10-deacethylbaccatinIII found in Taxus needles but the cost and difficulty of the extraction process of the semisynthetic precursors are also very high. The most promising approach for the sustainable production of taxol and related taxoids is provided by plant cell cultures at an industrial level.
INTRODUCTION
Throughout evolution the plant kingdom has developed a high diversity of plants, with only about half of over 500,000 existing species described to date. All plant organisms share essentially similar biochemical processes that permit them to complete the biological cycle. These metabolic pathways constitute the known primary metabolism. However, plants also produce a great variety of secondary compounds that are not essential for life but are very useful for their adaptation to the environment and their relationship with other organisms. These secondary metabolites represent the majority of plant natural products as well as more than 50% of the drugs used for medical purposes.
Among the main causes of human illness and death are tumour processes. For example, in 2002 it was estimated that there were 10.9 million new cases of cancer, 6.7 million deaths, and 24.6 million people living with the disease around the world [1] . In the United States, cancer is the second leading cause of mortality [2] , responsible for one in four deaths. Understandably, considerable effort is being invested in finding new natural products that might offer a cure for this disease.
The taxoids constitute a group of diterpene compounds characterised by the presence of the unusual taxane skeleton Fig. (1) , mainly found in Taxus (yew tree) species. At present, the chemical structure of more than one hundred taxoids is known, being classified according to the oxygenation of the C20 and the presence or not of lateral chains. The most important taxoids without the C13 lateral chain are baccatin III and its derived compounds, while the main taxoids with the C13 lateral chain are taxol, cephalomanine and their related compounds Taxol, registered as a trademark Taxol® by Bristol-Myers Squibb, and known generically as paclitaxel, is a secondary compound with a very complex chemical structure and one of the most effective anti-cancer drugs ever developed Fig. (2) . Extracted and identified in 1971 [3] from the inner bark of Taxus brevifolia (the pacific yew tree), this diterpene alkaloid is found in the inner bark Taxol: R 1 =Ac, R 2 =A 10-Deacetyltaxol: R 1 =Ac, R 2 =H Cephalomanine: R 1 =H, R 2 =H 10-Deacetylbaccatin: R 1 =H, R 2 =B of several Taxus species, but it accumulates in a very low concentration (about 0.02% of dry weight) and its extraction cost is extremely high. Furthermore, the use of inner bark for taxol production involves large-scale destruction of yew trees, a single tree yielding only enough taxol for about one dose of the drug. Consequently, the growing demand for taxol greatly exceeds the supply sustained by isolation from its natural source, and alternative sources of the drug are urgently being sought.
The most valuable taxoid is taxol, one kilogram costing about 300,000 US $, followed by 10-deacetylbacctin III and baccatin III. As mentioned above, the concentration of taxol in plants is usually only about 0.001 to 0.05% DW. However, T. baccata (the English yew tree) is a rich source of 10-deacetylbaccatin III, which reaches a concentration of about 0.3% in these plants. A kilogram of either of these taxol precursors, 10-deacetylbacctin III and baccatin III Fig. (2) , can be converted into about 0.6 to 0.7 kg taxol [4, 5] .
Although taxol has been prepared by total synthesis [6, 7a, 7b ], the process is not commercially viable. Taxol can also be produced semisynthetically from more abundant taxoids, for example, via the conversion of baccatin III and 10-deacetyl baccatin III found in Taxus needles [8] . However, extracting the semisynthetic precursors is also very expensive and difficult. The most promising approach for the sustainable production of taxol and related taxoids is provided by plant cell cultures at an industrial level.
DEVELOPMENT OF TAXOL AND PHARMACOLOGICAL STUDIES OF ITS ANTI-CANCER ACTION
Studies of the cytotoxic activity of taxol started in 1962 as part of a plant screening programme run jointly by the US National Cancer Institute (NCI) and the US Department of Agriculture (USDA). In 1964, the results obtained in in vitro models showed that the crude extracts of the bark of Taxus brevifolia presented cytotoxicity. The anti-cancer properties of taxol was confirmed in 1971 by Wani et al. [3] , who reported significant activity of taxol against L1210, P388 and P1534 leukaemia cells, Walker 256 carcinosarcoma and 180 and Lewis lung sarcomas in mice. Additionally, in 1976-1978 it was observed that this drug was effective against two difficult and slow-growing tumours: B16 melanoma and the LX-1 (lung), MX-1 (breast) and CX-1 (colon) xenografts. However, it was in 1979 when the development of taxol received a major boost, due to a report by Schiff and Horwitz [9] about its unique mode of action.
After studies on the dosage and pharmaceutically stable formulations of taxol, in 1984 Phase I clinical trials began in the USA, and in 1988 the drug's important activity against refractory ovarian cancer was announced. This encouraged a search for more abundant supplies of taxol so that the clinical trials could be extended.
The cost of drug development rises steeply once human trials have begun, and in 1991, in an effort to accelerate the progress of taxol's development as a drug, the NCI signed a cooperative agreement with the pharmaceutical company Bristol Myers to fund and carry out further work, including securing a greater supply of the drug. In return, the NCI provided Bristol Myers with the data it had assembled so far. The rate of collection of yew bark from Oregon and Washington increased so that more trials could be run. At the peak of this activity, several hundred thousand pounds of Pacific yew bark were being collected a year.
The Phase 2 clinical trials showed a good response (57%) of metastatic breast cancer to the taxol treatment [10] . The FDA (US Food and Drug Administration) granted marketing approval for taxol to treat refractory metastatic ovarian cancer and metastatic and refractory or anthracycline-resistant breast cancer in 1992 and 1994, respectively.
Addressing the supply problem, Bristol Myers found an alternative source of the compound in the common yew, Taxus baccata, which is widely grown as an ornamental and also T. wallichiana (the Himalayan yew tree). Both contain a taxol relative, 10-deacetyl baccatin III, which is relatively more abundant, and can be converted to taxol by chemical manipulation. 10-deacetyl baccatin III was obtained from the plant needles, a renewable source of the drug, and a semisynthetic process [11] , made possible a sustainable source of the compound of interest.
Again with a semisynthetic process, in1986, Potier and coworkers in France obtained the analogue docetaxel by using the precursor10-deacetylbaccatin III, extracted from needles of T. baccata, [8] . This drug was more readily available than taxol, because of the regenerating capacity of its source, and somewhat more soluble, allowing it to be developed more rapidly. In 1990 docetaxel, commercialized as Taxotere® by Rhône-Poulenc Rorer, Inc., entered Phase I clinical trials and in 1992 Phase II studies began. In 1996 and 1998 the FDA granted marketing approval for docetaxel in anthracycline-resistant breast cancer and metastatic breast cancer, respectively. It has been shown that docetaxel is approximately twice as potent as taxol as an inhibitor of microtubule depolymerization. In addition, docetaxel generates tubulin polymers that differ structurally from those generated by taxol and does not alter the number of protofilaments in the microtubules [12] .
Until now, the two taxoids described, taxol and docetaxel, have shown activity against several tumour processes, including nonsmall cell lung tumours, and those of the colon, skin, kidneys, ovaries, brain, breast, and prostate, as well as against the Kaposi sarcoma associated with AIDS and some leukaemias. Clinical trials to test taxol against other types of cancer and in combination with other therapies are currently in progress.
Since taxol is highly lipophilic and insoluble in water, but soluble in Cremophor EL, polyethylene glycols 300 and 400, chloroform, acetone, ethanol and methanol, it is formulated in 50% polyoxyethylated castor oil (Cremophor®) and 50% dehydrated alcohol for its clinical use. Docetaxel is also insoluble in water, but soluble in 0.1N hydrochloric acid, chloroform, dimethylformamide, 95%-96% v/v ethanol, 0.1N sodium hydroxide and methanol and is usually formulated in 100% polysorbate 80 and alcohol rather than in polyoxyethylated castor oil [13] . The effective clinical dose of both taxoids, taxol and docetaxel, depends on the cancer process. Taxol is generally well tolerated at usual dosages, especially 175 mg/m 2 over 3h and 24h weekly intravenous infusions, every 3 weeks. Nausea and vomiting are generally not significant problems. The hypersensitivity reactions that hindered the early development of paclitaxel have been almost totally eliminated by premedication with corticosteroids, diphenhydramine and ranitidine. Granulocytopenia is dose-dependent, thrombocytopenia is rare and alopecia is essentially universal. Additionally, myalgia, arthralgia and neurosensory changes are common at all doses and more frequent with shorter schedules. Docetaxel, whose safety pattern has been the subject of much debate, is generally used at 100 mg/m 2 every three weeks by 1-h intravenous infusions. As with taxol, granulocytopenia is common with docetaxel at 100 mg/m 2 . More troubling has been the fluid retention that appears with increasing duration of treatment and is manifested by pedal edema and serious effusions; however this problem can be avoided with the use of steroid premedication [14] .
Taxol and docetaxel are sometimes used in combination with other therapies, such as cisplatin, 5-fluoruracil, herceptin, etc. Herceptin is a monoclonal antibody with a specific action approved by the US in 2000 for the treatment of metastatic breast cancer with overexpreession of the protein HER2 (receptor 2 of the human epidermic growth factor), which is very numerous on the surface of cancer cells. At present, the combination of taxol or taxotere together with herceptin is highly recommended as a first line treatment for HER2-positive metastatic breast tumours. It is known that 23-30% of the breast cancer processes present HER2 overexpression.
In vitro studies with human liver microsomas and tissue slices showed that taxol is metabolized primarily to 6 -hydroxytaxol by the cytochrome P450 isozyme CY2C8 and to minor metabolites, 3'-p-hydroxytaxol and 6 ,3'-p-dihydroxypaclitaxel, by CYP3A4 [15] .
The primary anti-cancer drug in the battle against the disease is, for the present, taxol, which constitutes about 22% of all major cancer chemotherapy drugs on the world market. In 2000, BristolMyers Squibb reported its annual sales of Taxol® (Paclitaxel Injection) to be $1.592 billion -over $4.3 million per day, with current sales reaching more than $1 billion per year.
Under a long-term collaborative relationship with Bristol-Myers Squibb, Phyton has developed and commercialized a plant cell culture process for the production of taxol. Its German subsidiary, Phyton Gesellschaft für Biotechnik mbH, operates the world's largest dedicated plant cell culture production facility in Germany. This highly-automated and computer-controlled facility, with a largescale fermentor capacity of up to 75,000 litres, is being used for the production of taxol under current Good Manufacturing Practice conditions. Although the Phyton and Bristol Meyer's Squibb consortium is the most important supplier of taxol, other companies are also involved in the commercialization of this anti-cancerigen compound and several generic brands are now available. Despite the difficulties for their commercialization, cell cultures are viewed as having greater economical potential than the traditional cultivation system, since they can produce greater quantities of purer taxoids.
ACTION MECHANISM OF TAXOL AND STRUCTURE-ACTIVITY RELATIONSHIPS OF TAXOIDS
The action mechanism of taxol was discovered by Schiff and Horwitz [9] , whose work showed that taxol binds to assembled microtubules and blocks them from disassembling, hence inhibiting mitosis and cancer growth Fig. (3) . Thus, taxol has different properties from other cancer drugs, such as vincristine, vinblastine, podophyllin, etc., which stop the process of cell division and growth by preventing tubulin from assembling into microtubules.
Microtubules, as is well known, are constituted by tubulin dimers formed by two kinds of tubulin:
and Fig. (3) . Each monomer has about 450 amino acids with a 40% homology between them, and very similar structures [16] . The protein of each monomer has -helix and -pleated sheet regions. It also includes a region for nucleotide union, another for binding other proteins and a third for taxol binding.
There is a continuous dynamic equilibrium between tubulin dimers and microtubules, and consequently a continuous balance between polymerization and depolymerization. The maximum effects of taxol were found when the taxol/tubulin stoichiometric ratio was approximately 1/1 and tubulin polymerization was promoted with a concentration of taxol of 0.05 mM [17] . The binding of taxol to microtubules was found to be reversible, with a binding constant of about 0.9 μmol/L [18] .
Horwitz and co-workers had reported two photoaffinity labelling experiment results before the crystal structure of the , -tubulin dimer was known [19] . Later on, they showed that the [ 3 H]-labeled 3'-(p-azidobenzamido) group of the corresponding taxol analog binds to the N-terminal 31 amino acid in the -tubulin protein and that the 2-benzoyl group of taxol binds to 217-231 amino acids in the -tubulin protein sequence [20, 21] .
Comparing the dynamic properties of taxol and baccatin III Fig.  ( 2), similar interactions with tubulin were found in both molecules [22] , which supports the hypothesis that baccatin III (without the C13 side chain) is responsible for the majority of interactions with tubulin. However, Horwitz's research group [23] showed that the C-13 side chain was essential for taxol bioactivity. They reported that the C-13 side chain and C-2 benzoate act as anchors for binding the taxoid ring to tubulin. The oxetane ring of taxol is also involved in the taxol-tubulin interactions. Structure-activity relation- ship studies suggest that it plays a critical role in binding, either through taxoid skeleton rigidification and/or as a weak hydrogen binding acceptor, but the exact binding mechanism is not known [24] . In 1998 researchers at the Lawrence Berkeley Laboratory (LBL) produced the first high-resolution, three-dimensional image of the site where the anti-cancer drug taxol interacts with tubulin [25] . As reported by Ganesh et al., [26] , taxol needs a special conformation in T to be able to attach to the -monomer of tubulin.
THE SEARCH FOR NEW ANTI-CANCER TAXOL-RELA-TED COMPOUNDS
Although taxol has been established as one of the most effective anti-cancer drugs and is successfully used in clinics for the treatment of several metastatic tumours, new taxol related compounds with improved efficacy and less toxicity are being sought.
Due to the specificity of taxol binding to the -monomer of tubulin, it is very important to know the structure-activity relationships of taxoids in order to design new taxoids with improved antitumoral activity and water solubility. Wang, Itokawa and Lee [27] have described the functional groups of the taxol molecule necessary for such activity.
Knowing the importance of some functional groups of the taxol molecule has permitted more active and also more water-soluble chemical analogues to be obtained from baccatin III and 10-deacetylbaccatin III, such as Taxotere®, a trade mark of Rhône-Poulenc Rorer, Inc., whose generic name is docetaxel. As already indicated, this compound has high water solubility and is more than twice as effective as taxol against some cancer processes [28] Fig.  (4) .
In the ongoing search for taxol analogues that are active against tumour cells, changes in the chemical structure of taxol and, consequently, in its anti-cancer activity are being studied. (For more exhaustive information, see Fang and Liang, 2005 [29] ). The taxol molecule has a C-13 side chain and the taxoid core is formed by four rings known as A, B, C, and D Fig. (5) .
As mentioned previously, the C-13 side chain is essential for the bioactivity of taxol. Replacement of 3'-Ph with other alkyl or alkenyl substitutions usually improves taxol analogue activity, although the majority of the new analogues assayed have presented comparable or less activity than taxol. Cephalomanine Fig. (1) , which presents comparable cytotoxicity to taxol, also has a very similar structure, except that it has a tigloyl group in position C-3' of the C-13 side chain instead of a benzoyl group. Changes in the 3'-N-tigloyl group have been studied, but without obtaining any remarkable improvement in activity [30] .
Most of the A ring-nor analogues obtained by Kingston's group were less active than taxol in both cytotoxicity and tubulin polymerization tests [31] . Kingston's research group has also shown the positive role of the 1-OH group in taxol behaviour against cancer cells.
In relation to taxol analogues with changes in the B-ring and acyl substitutions at C-2, it was found [32] that the meta-substituted compounds were generally more cytotoxic than taxol, while paraand ortho-showed less activity. C-2 meta-and para-substituted benzamido analogues have also been prepared [33] , but, although some of them presented activity against human tumour cells, they are not an improvement on taxol.
The major human metabolite of taxol, 6 -OH taxol, is less cytotoxic and 6 -substituents do not significantly change the efficacy of the compound. Several 7-sulfur analogues have been obtained, among them 7 -MeS, 7 -MeOCH2S and 7-MeSCH2 ether of taxol (BMS-184476), that show better responses than taxol. The last of these compounds, currently in Phase I clinical trials, presented the highest activity in several in vivo tumor-bearing animal models, including the most taxol-resistant tumor HCC79 model of BMS [34] . The oxetane ring (ring D) of taxol is essential for the activity of the compound, although its role is not completely known. The analogues obtained with substitutions or changes in this ring have not presented any significant improvement on the activity of taxol, although they have led to a better understanding of the role played by this part of the taxol molecule in the stabilization of the drugtubulin complex [35] .
Another priority in anti-cancer drug studies has been the search for new taxol analogues with greater activity against multi-drug resistance tumours. Taxoids that are not good substrates for Pglycoprotein (a well-characterized human ABC transporter that regulates the distribution and bioavailability of drugs) show potent activity in drug resistant tumours. It has been shown that the replacement of the 3'-phenyl group in taxol with an alkenyl or alkyl group increases activity against drug-resistant cell lines by 1 or 2 orders of magnitude [36] , resulting in the synthesis of new taxol analogues. Particularly noteworthy is the discovery of new analogues with modifications not only in the 3'-phenyl group but also in the C2 and C10 positions, which have presented a very good R/S ratio (ratio of IC 50 in drug resistant cells to that for sensitive cells). While for taxol the R/S ratio is 112 and 300 in LCC6 and MCF-7 tumour breast cells, respectively, the aforementioned analogues presented R/S ratios of 0.89 -1.3 and 0.92-1.2 in the same cell lines [37] . Although taxol is administered by injection because of its inactivity when administrated orally, the combination of taxol and a P-gP inhibitor improves the bioavailability of the drug at the gastrointestinal level. The search for new taxol analogues effective against multi-drug resistant tumours has led to the discovery that there are some natural or semisynthetic taxoids that can restore the sensitivity of cells to taxol in multi-drug resistant tumours. Outstanding among them are taxinine, taxuspine, and baccatinIII derivatives with hydrophobic side chains at the C7 or C10 position. Some non-taxoid multi-drug resistant reversal compounds may share a common structure with some multi-drug resistant reversal taxoids. For example, chloroquine derivatives obtained after the attachment of hydrophobic moieties to the antimalarial drug chloroquine gave very good response against multi-drug resistance in vivo and in vitro when coinjected with taxol [38] .
Another area of development in the search for anti-cancer compounds is the synthesis of prodrugs of taxol with improved effectiveness. Due to the low water solubility and the adverse effects of chemotherapy attributed to the drug and also to the surfactant Cremophol EL included in the pharmaceutical formulation, it has been necessary to study the establishment of prodrugs with high water solubility and also with improved specificity. In the first prodrug group we can find taxol conjugated to amino acids, hydroxyl acids, sialic acid, polyol-carbonate, etc. in different positions of the molecule [29] . The resulting higher solubility permits a lower application dose and consequently, a decrease in drug toxicity. The second group includes promising prodrugs in which taxol is conjugated to molecules that improve its specificity. For instance, the attachment of small peptides capable of recognizing tumour cell surface receptors is a good strategy to improve specificity [39] . Similar results have been obtained conjugating taxol to other molecules such as hyaluronic acid [39] and antiimmunoglobulin secondary antibodies [40] .
BIOSYNTHESIS OF TAXOL
Taxol is a highly substituted, polyoxygenated cyclic diterpenoid characterized by the taxoid ring system, whose biosynthesis in Taxus plants is incompletely known. The terpenoids constitute an extremely wide group of secondary metabolites with a great variety of structures and functions. Some of them play an essential role in plants, acting as, for example, phytohormones, photosynthetic pig- ments, or structural components of membranes, whereas others are compounds that contribute to the defence responses and adaptation of plants to their environment. However, all of them are formed from the same precursors, isopenthenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP). In many plant organisms there exists a dichotomy in the biosynthesis of terpenoid precursors [41] Fig. (6) . In the cytosol, the classical mevalonate pathway produces IPP from acetyl coenzyme A for the biosynthesis of sterols, triterpenes and certain sesquiterpenes. The plastids are the site of the alternative non-mevalonate pathway that produces IPP and DMAPP from pyruvate and glyceraldehyde-3-phosphate leading to plastidic isoprenoids: monoterpenes, diterpenes and tetraterpenes. According to Eisenreich et al. [42] , their studies on taxol biosynthesis conclusively show that the taxoid ring system is not synthesized via mevalonate, which is consistent with its diterpenic nature. However, previous work carried out in 1991 and 1992, [43, 44, respectively] showed that when Taxus plants were supplied with labelled mevalonate, acceptable specific incorporation rates into taxol were obtained. At the same time, our results when using a cell suspension of T. media (T. cuspidate x T. baccata) supplemented with mevalonate suggest that under the conditions of our experiment both pathways could be involved [45] . It is currently accepted that although to some extent Taxus sp. cells could use the mevalonate pathway as a source of IPP for taxol yield, the main source of the universal terpenoid precursor for the biosynthesis of GGPP and, consequently, of taxol, is the plastidic non-mevalonate pathway [46] .
The first committed step of taxol biosynthesis is the cyclization of geranylgeranyl diphosphate (GGPP), which leads to the formation of taxa-(4,5), (11, 12) -diene, the first compound in the taxol biosynthetic pathway that presents the taxoid skeleton, Fig. (7) . This reaction is catalyzed by taxadiene synthase (TS), an enzyme formed by a monomeric protein of 79 kDa with properties similar to other terpenoid cyclases. The enzyme was purified and characterized by Hezari, Lewis and Croteau [47] and the gene that codifies for TS was identified and cloned by Wildung and Croteau [48] . The product of the reaction is then hydroxylated at the C5 position by the enzyme Cit P450 taxadiene-5 -hydroxylase (T5 H) to form taxa-4(20),11(12)-dien-5 -ol [49] . This enzyme, apart from its hydroxylating activity, also conditions the migration of the double bond from 4(5) to 4 (20) . These two metabolic steps, cyclization and hydroxylation, are slow, but they do not seem to be rate-limiting in taxol biosynthesis [50] .
The next step in the biosynthetic pathway that leads to taxol is catalyzed by a specific taxadiene-5 -ol-O-acetyl transferase (TDAT) that acylates taxa-4(20),11(12)-dien-5 -ol at the C5 position to form taxa-4(20),11(12)-dien-5 -yl-acetate [51] . This taxoid is then hydroxylated by a P450-dependent monooxygenase, found in T. cuspidata (the Japanese yew tree), which catalyzes the hy- (12)-dien-5 , 10 diol 5-acetate. The enzyme that controls this step, the taxoid 10 -hydroxylase (T10 H), has been cloned and functionally characterized in yeast [52] . In 2001, another Cyt P450-dependent hydroxylase was found that, using taxa-4(20),11(12)-dien-5 -ol as a substrate, leads to the formation of taxa-4(20),11(12)-dien-5 -13 -diol [53] . This enzyme, the taxol 13 -hydroxylase (T13 H), presented 63% identity and 67% similitude with the hydroxylase responsible for the hydroxylation at the C10 position. At the same time, the fact that this enzyme uses the same substrate as TDAT, the taxa-4(20),11(12)-dien-5 -ol, suggests that taxol biosynthesis is not a linear pathway and that there are branch points that can lead to other related taxoids. It was observed that this alternative step was especially frequent in cell cultures elicited with methyl jasmonate [54] .
Another Cyt P450-dependent hydroxylase (taxoid 14 -hydroxylase; T14 H) responsible for the production of taxa-4(20),11(12)-dien-5 -acetoxy-10 -14 -diol was found later [55] . This enzyme utilizes substrates already hydroxylated at the C10 position, but not those hydroxylated at the C13 position, suggesting that this enzyme cannot be involved in taxol production since this compound does not present any hydroxylation at the C14 position.
After the formation of taxa-4(20),11(12)-dien-5 ,10 -diol 5-acetate, hydroxylation at the C1, C2, C4 and C7 positions, oxidation of C9 and epoxidation at the C4C5 double bond take place in the taxol biosynthetic pathway. The order of the hydroxylations mediated by Cyt P450 enzymes is not completely known, but on the basis of the oxidation frequency of the taxoids found in cell cultures, a probable sequence could be: C5, C10, C2, C9, C13 and finally C1. It should be borne in mind that some of the considered taxoids might not participate in taxol formation or could be artefacts of the in vitro cultures, but this oxidation sequence has been validated by phylogenetic analyses of previously cloned taxoid P450 oxigenases [56] .
The formation of the oxetane ring is also very important, since it is essential for the anti-cancer activity of the taxol molecule. Different mechanisms for its formation have been proposed [57, 58, 59] but it is currently accepted that the process involves epoxidation of the 4(20) double bond followed by migration of the -acetoxy group from the C5 to the C4 position together with the expansion of the oxirane to the oxetane group, Fig. (8) .
It is possible that oxirane/oxetane formation precedes hydroxylation at C1 in taxol biosynthesis, and in this case the hypothetical polyhydroxylated intermediate would be a taxadien-hexaol rather than a heptaol hydroxylated at C1 [60] . The enzyme that epoxidates the C4-C20 double bond has not yet been functionally characterized and the expansion of the oxirane-to-oxetane ring is also an incompletely known step.
After the formation of the hypothetical polyhydroxylated precursor by the activity of the enzyme 2 -O-benzoyl transferase (DBT), the next compound obtained is 10-deacetyl-baccatin III. The enzyme 10-deacetyl-baccatinIII-10-O-acetyl transferase (DBAT) then acylates the hydroxyl group at the C10 position to form baccatin III, Fig. (9) .
An essential step in the taxol biosynthesis is the esterification of the C13 hydroxyl group of baccatin III with the -phenylalanoylCoA side chain, Fig. (9) . The side chain is obtained from the amino acid -phenyalanine by the action of phenylalanine aminomutase (PAM) [61] . An unknown ester CoA ligase probably activates the compound so it can bind to baccatin III. The enzyme that catalyzes the conjugation of the -phenylalanoyl -CoA side chain to baccatin III is C-13-phenylpropanoyl-CoA transferase (BAPT), yielding the compound 3'-N-debenzoyl-2'-deoxytaxol. This compound, by the action of an unknown Cyt P450-dependent hydroxylase that hydroxylates the C2' position and the enzyme 3'-N-debenzoyl-2'-deoxytaxol N-benzoyl transferase (DBTNBT) that conjugates benzoyl-CoA to 3'-N-debenzoyl-2'-deoxytaxol, yields taxol as a final compound [62] .
BIOTECHNOLOGICAL PRODUCTION OF TAXOL
Demands on the supply of taxol continue to grow as a result of its expanding use in early intervention therapies as well as in combination with other chemotherapeutic agents. Due to the problems involved in its extraction from natural sources and the difficulties of semisynthetic production, the main efforts to obtain large amounts of this anti-cancer drug are based on cell cultures. The biotechnological production of taxol has been studied since the early 1990s. Early work carried out by different research teams [63, 64, 65] showed that calli and cell suspensions obtained from young stems of Taxus sp. were able to produce taxol at least to the same extent as the plant.
In order to increase the productivity of taxol and related taxoids in cell and tissue cultures, various strategies, including optimisation of culture conditions, selection of high-producing cell lines, use of elicitors, and addition of precursors, have been examined by many researchers [66, 67, 68, 69, 70, 71] . There are excellent reviews about the biotechnological production of taxol and the present knowledge of its metabolism in cell cultures [56, 72, 73, 74, 75, 76] . Table 1 summarises the most significant recent studies on the capacity of cell cultures to improve their taxol production and the main strategies used to achieve this aim.
In order to develop a biotechnological system for a high taxol production, our research group has optimized the culture conditions by assaying several basic media, PGRs, sugar supplements etc. As secondary metabolite production in plant cell cultures does not usually depend on growth, a two-stage culture system has been established. Plant cells are first cultured in a medium optimised for their growth, which is then replaced by a production medium that mainly stimulates the biosynthesis of secondary metabolites. This system has the added advantage of permitting the addition of biosynthetic precursors and elicitors when the secondary metabolite production is at its highest, that is, during the culture's second stage. As shown in Fig. (10) , taxol production was clearly enhanced by the transfer of cells from the medium promoting growth to the optimum medium for taxoid production [69] .
Generally, when plant cells perceive environmental changes via specific receptors or perception mechanisms, they generate biological responses through specific signal transduction. The accumulation of taxol and related taxoids in Taxus plants is thought to be a biological response to specific external stimuli [66] . Jasmonates have been reported to play an important role in a signal transduction process that regulates defence genes in plants [77] . Exogenously applied methyl jasmonate enhances production of secondary metabolites in a variety of plant species, and in particular it is the most effective chemical for eliciting taxoid production in various Taxus suspension cultures [69, 78, 79] Other elicitors and various strategies have been studied in order to increase taxol production in Taxus sp cell cultures, as indicated in Table (1) . Moreover, the development of Taxus cell cultures capable of producing significant amounts of taxol and related taxoids, and that are inducible by elicitation, provides an excellent tool to improve our understanding of how the biosynthesis of these compounds can be regulated in vitro. All stereoisomers of methyl jasmonate were prepared, and their effects on cell yield and promotion of taxol and baccatin III production investigated in cell suspension cultures of T. media.
A two-stage culture for T. media cell suspension was carried out using a 5-l stirred bioreactor. A content of 21.12 mg l -1 of taxol and 56.03 mg l -1 of baccatin III was obtained after 20 days of culture.
The effects of inoculum size and age on biomass growth and taxol production of elicitor-treated T. yunnanensis cell cultures were studied. Growth rate and capacity to accumulate taxol and baccatin III were measured.
Suspension cultures of T. baccata and T. wallichiana were grown in a 20.l bioreactor, and their growth rate and capacity to accumulate taxol and baccatin III were measured.
The kinetics of growth and production of taxol and baccatin III by a cell suspension of T. wallichiana were compared in shake flasks and a 20-l airlift bioreactor.
The synergistic effects of various elicitors were investigated in the suspension cultures of T. chinensis, and the results showed that the mixtures of elicitors with different acting paths could give a synergistic effect in taxol production while those with the same acting paths could not.
Taxol transport in T. baccata suspension cultures was studied using [ The work describes the principal taxoids produced by T. media cell suspension cultures during normal growth and upon elicitation with methyl jasmonate.
The influence of elicitors on taxoid production and 3-hydroxy-3-methylglutaril coenzyme A reductase activity in T. media cells was studied.
Enhancement of taxol release from the producer cells to the medium by cell wall digesting enzymes
The effects of low-energy ultrasound on oxidative burst, jasmonic acid biosynthesis and taxol production in T. chinensis suspension cultures were investigated.
Two groups of replicate T. cuspidata cell cultures were generated either with a mixing flask or segregation of parental flasks at each subculture. The production level of taxol in subcultures resulting from mixing inocula was sustained at a higher level than from segregated subcultures, which is consistent with the possibility of taxol production being induced by cell signaling within the population.
The effect of alternating and direct current magnetic fields on growth and taxol production in cell cultures of T. chinensis var. mairei was studied.
The induction by methyl jasmonate and salicylic acid (SA) of taxol and relevant taxoid biosynthesis in suspension cultures of T. chinensis was studied. The results indicate that SA might increase taxol production by blocking the biosynthesis pathway from baccatin III to cephalomannine.
The production of taxol and baccatin III using free and immobilized cells of T. baccata was investigated in three different bioreactor types (stirred, airlift and wave). The stirred bioreactor was the most efficient in promoting immobilised cell production of taxol, giving a content of 43.43 mg l -1 at 16 days off culture.
Taxol production was enhanced in T. chinensis cell suspension cultures adapted to chitosan, when treated with Ag + and methyl jasmonate. The capacity of cells to excrete taxol to the medium was also improved.
The response of T. yunnanensis (the yew tree from the Chinese province of Yunnan) cell cultures to heat shock was studied. The cells were heat shocked at 35-50ºC for 30-60 min. Taxol production was clearly induced and cell viability decreased. The addition of ABA to the culture was assayed.
The elicitation mechanism in T. cuspidate cell cultures when supplemented with Ce 4+ or methyl jasmonate was studied. The results showed that the elicitation involves lipidic constituents of the cell membrane. Taxol production was enhanced. After optimizing the culture conditions and environmental and physical factors, the next step for the large-scale production of valuable secondary compounds is to scale up the culture. Bioreactors are needed because they can be applied to large-scale production and also because they allow a greater control of the culture conditions.
We compared the taxoid levels achieved by T. media cell cultures grown in Erlenmeyer flasks and in a stirred bioreactor. In both cases, the studied cell line was cultured in the production medium with the addition of methyl jasmonate. We found that scaling up improved the production of taxol and baccatin III 2.4-and 9 -fold, respectively [69] .
The successful cultivation of Taxus cells for taxol production has been carried out in different types of bioreactors: pneumatically mixed and stirred tank [96] ; Wilson-type [97] ; balloon-type bubble, bubble-column, with split-plate internal loop, with concentric draught-tube internal loop, with fluidized bed and stirred tank [98] ; airlift [83, 84] ; turbine stirred tank [69] ; turbine stirred tank, tower airlift and wave [71] . We have studied taxol and baccatin III production in a stirred bioreactor running for 30 days with or without the addition of methyl jasmonate. The highest total content of taxol (21.12 mg l -1 ) and baccatin III (55.63 mg l -1 ) in the studied Taxus media cell cultures, both reached on day 20 (after 8 days of culture in the production medium), was 9-and 26-fold higher, respectively, in the culture supplemented with methyl jasmonate (100 μM) Fig.  (11) .
The fact that there was a greater accumulation of taxol and baccatin III in the bioreactor culture than in the shake flask culture (factors of 1.4 and 5.4, respectively) when both were at their productive peak confirms the suitability of the selected growth conditions used in the bioreactor culture.
The taxol and baccatin III yields obtained in these conditions are among the highest reported by academic laboratories. However, much higher taxol levels (a maximum level of 295 mg l -1 reached at day 14; [73] ) have been reported by industrial groups.
Numerous studies have reported the immobilization of plant cell suspensions to enhance the production of valuable plant metabolites. This increase is due to the higher cell concentration per unit of volume, better cell-cell contact and more favourable conditions for cell differentiation.
The taxol production in T. baccata cell cultures clearly improved when cell suspensions were immobilised in 2% alginate beads and cultured in a stirred bioreactor, using the optimum medium for taxol biosynthesis with the addition of methyl jasmonate, Fig. (12) . When the taxol production was at its highest (43.5 mg L -1 ), on day 16, the levels of this taxoid were more than 5 times higher than those obtained by the same cell line growing free in the same conditions [71] .
FUTURE PERSPECTIVES
Plant cell cultures constitute a promise and almost a reality for the controlled production of a great deal of secondary compounds of interest, although most of the bioprocesses developed up to now have not turned out to be commercially viable. The main studies carried out during the last decades have been empirical. Empirical research involves the optimization of the culture system, considering the known in-put factors (such as cell line selection, culture media, culture conditions, elicitors, culture in bioreactors ...) and out-put factors (growth, production, yield, etc…). These studies have permitted the improvement of taxol and related taxoid production in cell cultures of different Taxus species. However, to develop successful strategies and technologies, it is also necessary to take a rational approach to the molecular bioprocesses of plant cells, based on the comprehension of biosynthetic pathways and their regulation. As this review demonstrates, knowledge of taxol biosynthesis has significantly improved and almost all the metabolic steps, the enzymes involved and genes that codify for these enzymes have been reported. However, in order to improve production, the control of each metabolic step contributing to taxol formation, especially the flux limiting steps, needs to be more extensively studied. It is essential to explore how the different factors that improve taxoid biosynthesis and accumulation also affect the metabolic profiles and genetic expression in Taxus spp cell cultures.
Knowledge of the genes involved in the key steps of the taxol biosynthetic pathway and their regulation, coupled with advanced bioanalytical and metabolic engineering techniques, will permit transgenic cell cultures overexpressing the genes of interest to be obtained, and consequently will lead to the establishment of highly productive cell cultures at an industrial level.
Increased understanding of the processes that take place in tumorous cells as well as the advanced studies on the relationships between anti-cancer drugs and tumour processes, backed up by an abundant supply of taxol and/or related taxoids, could constitute a great step forward in the fight against cancer.
